Page last updated: 2024-12-10

chlorpheniramine maleate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281068
CHEMBL ID1659
CHEBI ID3645
SCHEMBL ID33357
MeSH IDM0004192

Synonyms (205)

Synonym
AC-267
smr000653461
(+/-)-chlorpheniramine maleate salt
MLS001148230
allergin
EU-0100261
(+/-)-chlorpheniramine maleate salt, >=99% (perchloric acid titration)
PRESTWICK_57
MLS001424173
efidac 24 chlorpheniramine maleate
pyridamal-100
antagonate
piriton
polaronil [german]
histadur dura-tabs
chlor-trimeton allergy
neorestamin
chlorpheniramine maleate oros tablets
chlor-trimeton maleate
carbinoxamide maleate
1-p-chlorophenyl-1-(2-pyridyl)-3-dimethylaminopropane maleate
ccris 1418
chlor-trimeton od
chlorphenamine hydrogen maleate
kloromin
dl-chlorpheniramine maleate
gamma-(4-chlorophenyl)-n,n-dimethyl-2-pyridinepropanamine(z)-2-butenedioate (1:1)
chlor-tripolon
1-(n,n-dimethylamino)-3-(p-chlorophenyl-3-alpha-pyridyl)propane maleate
1-(p-chlorphenyl)-1-(2-pyridyl)-3-dimethylaminopropan maleat [german]
pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethyl)benzyl)-, maleate (1:1)
allerclor
2-(p-chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine maleate (1:1)
lorphen
alunex
ibioton
histaspan-plus
chlor-trimeton injection
piriex
c-meton
pyridamal 100
chlormene
2-pyridinepropanamine, gamma-(4-chlorophenyl)-n,n-dimethyl-, (z)-2-butenedioate (1:1)
chloroprophenpyridamine maleate
synistamin
nci-c55265
dl-2-(p-chloro-alpha-2-(dimethylamino)ethylbenzyl)pyridine maleate
histaspan-d
einecs 204-037-5
dehist
ru-tuss capsules
chlorpheniramine maleate
C07780
113-92-8
smr000466271
MLS000758311
chlor-trimeton (tn)
chlorpheniramine maleate (jp17/usp)
teldrin (tn)
D00665
(?)-chlorpheniramine maleate
NCGC00093720-01
NCGC00093720-02
maleate, chlorpheniramine
HMS2051L14
HMS2093N19
( inverted question mark)-chlorpheniramine maleate
C 3025
HMS501N18
chlorphenamine maleate
HMS1568G16
CHEMBL1659
nsc-756684
pyridamal
chebi:3645 ,
chlorphenamini hydrogenomaleas
histaspan
chlorprophenpyridamine maleate
efidac
HMS3260F04
HMS2095G16
chlorpheniramine maleate [usp:jan]
sildec pe
zodryl ac 25
lohist
unii-v1q0o9oj9z
2-pyridinepropanamine, gamma-(4-chlorophenyl)-n,n-dimethyl-, (2z)-2-butenedioate (1:1)
zodryl ac 50
nsc 756684
corfen
phenalin
zodryl ac 60
sine off
m.p. chlorcaps t.d.
zodryl ac 30
chlor-trimeton 12 hour
v1q0o9oj9z ,
zodryl ac 40
1-(p-chlorphenyl)-1-(2-pyridyl)-3-dimethylaminopropan maleat
zodryl ac 80
medique chlorphen
nasohist
alka-seltzer plus
pharmakon1600-01505530
nsc759156
chlortrimeton
AKOS015951220
HMS2230F21
HMS2232B23
CCG-101036
LP00261
(+/-)-chlorpheniramine maleate
S1816
DBAKFASWICGISY-BTJKTKAUSA-N
demazin component chlorpheniramine maleate
chlorphenamine maleate [ep monograph]
codimal-l.a. 12 component chlorpheniramine maleate
chlorpheniramine maleate component of advil allergy sinus
chlorphenamine maleate [who-dd]
chlorpheniramine maleate [usp-rs]
2-(p-chloro-.alpha.-(2-(dimethylamino)ethyl)benzyl)pyridine maleate (1:1)
chlorpheniramine maleate component of demazin
advil allergy sinus component chlorpheniramine maleate
chlorpheniramine maleate component of isoclor
chlorpheniramine maleate [jan]
drize component chlorpheniramine maleate
isoclor component chlorpheniramine maleate
ornade component chlorpheniramine maleate
chlorpheniramine maleate [vandf]
chlorpheniramine maleate component of triaminic
chlorpheniramine maleate [mi]
chlorpheniramine maleate [orange book]
chlorpheniramine maleate component of drize
chlorpheniramine maleate component of contac
chlorphenamine maleate [mart.]
triaminic component chlorpheniramine maleate
2-pyridinepropanamine, .gamma.-(4-chlorophenyl)-n,n-dimethyl-, (z)-2-butenedioate (1:1)
chlorphenamini hydrogenomaleas [who-ip latin]
chlorpheniramine maleate component of codimal-l.a. 12
chlorpheniramine maleate [usp monograph]
chlorphenamine hydrogen maleate [who-ip]
contac component chlorpheniramine maleate
chlorpheniramine maleate component of ornade
CCG-221565
CCG-220117
chlorpheniramine (maleate)
HY-B0286A
NC00286
SCHEMBL33357
(y)-chlorpheniramine maleate
tox21_500261
NCGC00260946-01
3-(4-chlorophenyl)-n,n-dimethyl-3-(pyridin-2-yl)propan-1-amine maleate
F2173-0923
W-108612
(a+/-)-chlorpheniramine maleate
chlorpheniramine maleate salt
mfcd00069225
chlorphenamine maleate, european pharmacopoeia (ep) reference standard
SR-01000075261-9
sr-01000075261
chlorpheniramine maleate, united states pharmacopeia (usp) reference standard
D70131
chlorpheniramine maleate, pharmaceutical secondary standard; certified reference material
SR-01000075261-1
HMS3712G16
SW196372-4
(z)-but-2-enedioic acid;3-(4-chlorophenyl)-n,n-dimethyl-3-pyridin-2-ylpropan-1-amine
Q27106157
AS-13167
AMF0009
HMS3884O10
puermin
chlorophenaminemaleate
chlorphenaminemaleate
[3-(4-chloro-phenyl)-3-pyridin-2-yl-propyl]-dimethyl-amine maleate
ed chlorped jr
allergy time
gamma-(4-chlorophenyl)-n,n-dimethyl-2-pyridinepropanamine (z)-2-butenedioate
wal-finate
chlorphenamine maleate (mart.)
anti allergy
clear choice allergy relief
allergy relief4 hour
only forallergy
chlorpheniramine maleate (usp monograph)
histalen
clorrelief
cvshealth childrens allergy relief pops
chlortabs
pharbechlor
chlorphenamine maleate (ep monograph)
chlorpheniramine maleate 4 mg
chlorpheniramine maleate 4mg
chlorpheniramine maleate (usp:jan)
chlorphen-12
histapan
clorrelief kids
haben herb
sprinsol
dl-2(-p-chloro-alpha-2-(dimethylamino)ethylbenzyl)pyridine bimaleate
chlorpheniramine maleate (usp-rs)
chlor-allergy 4-hour
(+/-)-chlorpheniramine.maleate
(+/-)-chlorpheniramine.maleate, 1mg/ml in methanol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.01190.044717.8581100.0000AID485294
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID504466
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency75.686323.934123.934123.9341AID1967
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency1.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.00460.004611.374133.4983AID624296
lamin isoform A-delta10Homo sapiens (human)Potency5.62340.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency12.58930.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (60)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID396318Sedative-hypnotic activity in Swiss Albino mouse assessed as CNS depression at 5 mg/kg, po after 1 hr2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID251600Percentage reduction central nervous system depression in guinea pig by compound2005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Synthesis and pharmacological investigation of novel 1-substituted-4-phenyl-1,2,4-triazolo[4,3-a]quinazolin-5(4H)-ones as a new class of H1-antihistaminic agents.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID78155In vitro inhibition of histamine-induced contractions in guinea pig ileum1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis of 2-(4-substituted-1-piperazinyl)benzimidazoles as H1-antihistaminic agents.
AID396317Antihistaminic activity against Dunkin-Hartley guinea pig assessed as protection against histamine-induced bronchospasm at 25 mg/kg, ip2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID396320Sedative-hypnotic activity in Swiss Albino mouse assessed as CNS depression at 5 mg/kg, po after 3 hrs2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1301219Antihistaminic activity in guinea pigs assessed as supression of histamine induced bronchospasm2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
Quinazolines and quinazolinones as ubiquitous structural fragments in medicinal chemistry: An update on the development of synthetic methods and pharmacological diversification.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1717078Antiinflammatory activity in histamine-induced paw edema in Balb/c mouse assessed as inhibition of paw edema at 1 mg/kg, ip administered 1 hr prior to histamine challenge and measured after 1 hr relative to control2020European journal of medicinal chemistry, Jan-15, Volume: 186Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID252138Percentage protection of guinea pigs from histamine induced bronchospasm by compound2005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Synthesis and pharmacological investigation of novel 1-substituted-4-phenyl-1,2,4-triazolo[4,3-a]quinazolin-5(4H)-ones as a new class of H1-antihistaminic agents.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1717079Antiinflammatory activity in histamine-induced paw edema in Balb/c mouse assessed as inhibition of paw edema at 1 mg/kg, ip administered 1 hr prior to histamine challenge and measured after 5 hrs2020European journal of medicinal chemistry, Jan-15, Volume: 186Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID396319Sedative-hypnotic activity in Swiss Albino mouse assessed as CNS depression at 5 mg/kg, po after 2 hrs2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID76797In vivo for the inhibition of histamine-induced mortality in guinea pig1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis of 2-(4-substituted-1-piperazinyl)benzimidazoles as H1-antihistaminic agents.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.55)18.7374
1990's0 (0.00)18.2507
2000's5 (22.73)29.6817
2010's11 (50.00)24.3611
2020's5 (22.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 116.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index116.98 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index223.53 (26.88)
Search Engine Supply Index2.12 (0.95)

This Compound (116.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]